These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9540175)

  • 21. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
    Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
    Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
    Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amifostine: a radioprotector in locally advanced head and neck tumors.
    Wagner W; Prott FJ; Schonekas KG
    Oncol Rep; 1998; 5(5):1255-7. PubMed ID: 9683846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
    Anné PR; Machtay M; Rosenthal DI; Brizel DM; Morrison WH; Irwin DH; Chougule PB; Estopinal NC; Berson A; Curran WJ
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):445-52. PubMed ID: 17141978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
    Nicolatou-Galitis O; Sotiropoulou-Lontou A; Velegraki A; Pissakas G; Kolitsi G; Kyprianou K; Kouloulias V; Papanikolaou I; Yiotakis I; Dardoufas K
    Oral Oncol; 2003 Jun; 39(4):397-401. PubMed ID: 12676261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Outcome of primary combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine].
    Schultze J; Kimmig B
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():13-7. PubMed ID: 10584134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
    Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
    Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
    Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
    Haddad R; Wirth L; Costello R; Weeks L; Posner M
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):84-8. PubMed ID: 14727246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials.
    Gu J; Zhu S; Li X; Wu H; Li Y; Hua F
    PLoS One; 2014; 9(5):e95968. PubMed ID: 24788761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective effect of amifostine on dental health after radiotherapy of the head and neck.
    Rudat V; Meyer J; Momm F; Bendel M; Henke M; Strnad V; Grötz K; Schulte A
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1339-43. PubMed ID: 11121631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.